Vyriad will construct anti-cancer vaccine manufacturing facility

| By | Cancer Drugs, Pharmaceutical Plant Construction

Vyriad, a clinical-stage biotechnology company developing novel oncolytic virus therapies for the treatment of cancers, announced the signing of a contract to build out its facility in the IBM Campus (Rochester, Minnesota, USA).

The building plans include offices, research laboratories, and a state-of-the-art Good Manufacturing Practice (GMP) facility for production of the company’s clinical-stage oncolytic virus therapies that are in development for the treatment of various cancers.

Oncolytic virotherapy is rapidly emerging as a cornerstone for immuno-oncology treatment regimens. Vyriad’s oncolytic immunovirotherapy products are based on the company’s engineered Oncolytic Vesicular Stomatitis Virus (VSV) and Oncolytic Measles Virus platforms that enable selective destruction of cancer cells without harming normal tissues. Vyriad’s product development pipeline encompasses multiple clinical- and preclinical-stage programs that target a broad range of cancer indications as well as programs that pair the company’s oncolytic viruses with other cancer immunotherapy modalities, traditional cancer therapy, and newer targeted therapies.

The company previously received a $10 million financing in July of 2017 to fund its ongoing clinical trials. The new manufacturing facility will enable production, quality-control testing, and supply of clinical-grade oncolytic virus therapies for later-stage clinical studies. Vyriad is commencing the initial buildout immediately and plans to have the facility fully operational in Q4 2018.

SOURCE: vyriad
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.